CA3023802C - ACTIVATING AGENTS OF THE DIFFERENTIATION CLUSTER 47 FOR USE IN THE TREATMENT OF INFLAMMATION - Google Patents

ACTIVATING AGENTS OF THE DIFFERENTIATION CLUSTER 47 FOR USE IN THE TREATMENT OF INFLAMMATION

Info

Publication number
CA3023802C
CA3023802C CA3023802A CA3023802A CA3023802C CA 3023802 C CA3023802 C CA 3023802C CA 3023802 A CA3023802 A CA 3023802A CA 3023802 A CA3023802 A CA 3023802A CA 3023802 C CA3023802 C CA 3023802C
Authority
CA
Canada
Prior art keywords
agent
inflammation
use according
peptide
age
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3023802A
Other languages
English (en)
French (fr)
Other versions
CA3023802A1 (en
Inventor
Florian Sennlaub
Michael HOUSSET
Xavier GUILLONNEAU
Jose-Alain Sahel
Philippe Karoyan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Centre National de la Recherche Scientifique
Institut National de la Santé et de la Recherche Médicale
Sorbonne Université
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Sorbonne Université filed Critical Centre National de la Recherche Scientifique
Publication of CA3023802A1 publication Critical patent/CA3023802A1/en
Application granted granted Critical
Publication of CA3023802C publication Critical patent/CA3023802C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3023802A 2016-05-10 2017-05-10 ACTIVATING AGENTS OF THE DIFFERENTIATION CLUSTER 47 FOR USE IN THE TREATMENT OF INFLAMMATION Active CA3023802C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16169072 2016-05-10
EP16169072.2 2016-05-10
EP17154452 2017-02-02
EP17154452.1 2017-02-02
PCT/EP2017/061151 WO2017194586A1 (en) 2016-05-10 2017-05-10 Agents that activate cd47 and their use in the treatment of inflammation

Publications (2)

Publication Number Publication Date
CA3023802A1 CA3023802A1 (en) 2017-11-16
CA3023802C true CA3023802C (en) 2025-02-04

Family

ID=58772857

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3023802A Active CA3023802C (en) 2016-05-10 2017-05-10 ACTIVATING AGENTS OF THE DIFFERENTIATION CLUSTER 47 FOR USE IN THE TREATMENT OF INFLAMMATION

Country Status (5)

Country Link
US (1) US11142548B2 (enExample)
EP (1) EP3454884B1 (enExample)
JP (3) JP7537074B2 (enExample)
CA (1) CA3023802C (enExample)
WO (1) WO2017194586A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11142548B2 (en) * 2016-05-10 2021-10-12 Sorbonne Universite Agents that activate CD47 and their use in the treatment of inflammation
CN111655253A (zh) 2018-01-09 2020-09-11 杨百翰大学 用于用汉黄芩素治疗疼痛的组合物和方法
WO2022113887A1 (ja) * 2020-11-27 2022-06-02 京都府公立大学法人 炎症性網膜疾患の判定方法、炎症性網膜疾患治療剤、及び炎症性網膜疾患治療剤のスクリーニング方法
EP4329825A4 (en) * 2021-04-26 2025-03-26 President and Fellows of Harvard College CD47 COMPOSITIONS AND METHODS FOR THE TREATMENT OF DEGENERATIVE EYE DISEASES
CN116831988A (zh) * 2023-06-13 2023-10-03 南京鼓楼医院 一种载肽模拟物pkhb1的脂质体眼用制剂及其制备方法
WO2026062098A1 (fr) 2024-09-18 2026-03-26 Sorbonne Universite Nouvelles protéines activatrices de cd47

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US6001962A (en) 1996-11-15 1999-12-14 The Regents Of The University Of California Modified Fas ligands
CA2226962A1 (en) * 1998-02-16 1999-08-16 Marie Sarfati Use of binding agents to cd47 and its ligands in the treatment or the prophylaxis of various inflammatory, autoimmune and allergic diseases and in the treatment of graft rejection
WO1999065935A2 (en) 1998-06-18 1999-12-23 Karolinska Innovations Ab Fas peptides and antibodies for modulating apoptosis
DK2447275T3 (en) 2006-07-13 2015-06-29 Univ Iowa Res Found Methods and reagents for the treatment of age-related macular degeneration
BRPI0923442A2 (pt) 2008-12-19 2016-01-12 Novartis Ag polipeptídeos solúveis para uso em tratamento de distúrbio autoimunes e inflamatórios.
CA2766039A1 (en) 2009-06-29 2011-01-20 The Board Of Regents Of The University Of Texas System Arginase formulations and methods
WO2011137363A1 (en) 2010-04-30 2011-11-03 Allergan, Inc. Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase
AU2011252851B2 (en) 2010-05-14 2016-10-06 The Board Of Trustees Of The Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to CD47
US20140127269A1 (en) * 2012-02-13 2014-05-08 The Schepens Eye Research Institute, Inc. Anti-Inflammatory Peptide Derived From Thrombospondin-1 and Uses Thereof
EP3434276B1 (en) 2012-06-06 2024-10-30 Pepkon Method and pharmaceutical composition for use in the treatment of cancer
US10004780B2 (en) 2012-10-17 2018-06-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of age-related macular degeneration (AMD)
EP3087182B1 (en) 2013-12-23 2019-03-20 Memorial Sloan-Kettering Cancer Center Methods and compositions for treating cancer using peptide nucleic acid-based agents
EP2898896A1 (en) * 2014-01-22 2015-07-29 Université Pierre et Marie Curie (Paris 6) Agents for use in the treatment of retinal inflammation
JP6613304B2 (ja) 2014-09-17 2019-12-04 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 抗ｃｄ２７６抗体（ｂ７ｈ３）
EP3206703B1 (en) 2014-10-14 2021-05-19 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Peptide for treating pancreatic cancer
FR3036620B1 (fr) * 2015-05-27 2017-09-01 Inst Biophytis Utilisation de 3-desoxyanthocyanidines pour le traitement de maladies oculaires
US11142548B2 (en) * 2016-05-10 2021-10-12 Sorbonne Universite Agents that activate CD47 and their use in the treatment of inflammation

Also Published As

Publication number Publication date
EP3454884A1 (en) 2019-03-20
JP7537074B2 (ja) 2024-08-21
US11142548B2 (en) 2021-10-12
US20190225649A1 (en) 2019-07-25
CA3023802A1 (en) 2017-11-16
JP2023179752A (ja) 2023-12-19
WO2017194586A1 (en) 2017-11-16
JP2022078244A (ja) 2022-05-24
JP7822577B2 (ja) 2026-03-03
EP3454884B1 (en) 2023-07-12
JP2019521963A (ja) 2019-08-08

Similar Documents

Publication Publication Date Title
JP7822577B2 (ja) Ｃｄ４７を活性化する作用物質およびその炎症治療における使用
US12006364B2 (en) Anti-CD100 antibodies and methods for using the same
US11999779B2 (en) Anti-complement factor C1q Fab fragments and uses thereof
AU2017203611B2 (en) Compositions and methods for growth factor modulation
US12358991B2 (en) Anti-Sortilin antibodies and methods of use thereof
KR20180012856A (ko) 면역반응의 조절을 위한 방법 및 폴리펩타이드
KR20180034518A (ko) 혈관신생 및 신혈관형성 관련 장애를 치료하는 방법
US20210386837A1 (en) Active low molecular weight variants of angiotensin converting enzyme 2 (ace2) for the treatment of diseases and conditions of the eye
KR102591737B1 (ko) 가령 황반 변성증 치료용 펩티드
US20140288010A1 (en) Compositions and Methods for Increasing Stem Cell Survival
KR20250041621A (ko) 질환 조절제에 접합된 igf-1r 리간드를 사용한 눈의 염증성 병태의 치료 방법
EP3394100B1 (en) Agents that inhibit the binding of cfh to cd11b/cd18 and uses thereof
KR20210021992A (ko) 망막 색소 변성증 치료용 펩티드
WO2009095916A2 (en) Cd14 and peptides thereof for protection of cells against cell death

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220317

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20241122

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241122

Q17 Modified document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q17-Q103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DOCUMENT PUBLISHED

Effective date: 20250131

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-4-4-F10-F11-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: GRANT BY ISSUANCE

Effective date: 20250204

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250507

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250507

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260506

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260506